MA vs ZYME · P/E 38, rev $32.79B vs rev $76.3M
Mastercard Inc (MA) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
Mastercard Inc (MA) is a credit services company listed on US. It is led by Michael Miebach.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported MA revenue for 2025-12-31 was $32.79B. Net income was $14.97B. Revenue was up 16.4% from 2024-12-31 to 2025-12-31. MA currently screens at market cap $515.12B and trailing P/E 38.4.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
MA currently screens at market cap $515.12B and trailing P/E 38.4. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the MA and ZYME stock pages for the full models.
Not investment advice.